Ignite Creation Date:
2024-05-06 @ 7:55 AM
Last Modification Date:
2024-10-26 @ 11:53 AM
Study NCT ID:
NCT02623972
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-02-06
First Post:
2015-12-02
Brief Title:
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Study Overview
Official Title:
A Phase 2 Study of Eribulin Followed by Doxorubicin and Cyclophosphamide as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This research study is studying a drug called eribulin combined with standard treatment as a possible preoperative treatment for HER2 negative inflammatory breast cancer
Detailed Description:
This research study is a Phase II clinical trial Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease Investigational means that the intervention is being studied
Eribulin works by interfering with cancer cell division growth and spread
The goal of this research study is to evaluate inflammatory breast cancers response to treatment with eribulin followed by AC chemotherapy Cohort A and also the response to treatment with AC followed by Eribulin Cohort B when given as a preoperative chemotherapy treatment for participants with HER2 negative inflammatory breast cancer
Eribulin works by interfering with cancer cell division growth and spread
The goal of this research study is to evaluate inflammatory breast cancers response to treatment with eribulin followed by AC chemotherapy Cohort A and also the response to treatment with AC followed by Eribulin Cohort B when given as a preoperative chemotherapy treatment for participants with HER2 negative inflammatory breast cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None